Chemomab Therapeutics (CMMB) Restructuring Costs (2020)
Chemomab Therapeutics posted quarterly Restructuring Costs of -$699000.0 for Q4 2020, down 984.81% on a QoQ basis from $79000.0 in Q3 2020.
Chemomab Therapeutics (CMMB) has 1 years of Restructuring Costs data on file, last reported at -$699000.0 in Q4 2020.
- For the quarter ending Q4 2020, Restructuring Costs changed N/A year-over-year to -$699000.0; the trailing twelve-month figure through Dec 2020 stood at $50000.0 (changed N/A YoY), and the FY2021 full-year result was $216000.0, up 332.0% from the prior year.
- Restructuring Costs for Q4 2020 stood at -$699000.0, down from $79000.0 in the prior quarter.
- Across five years, Restructuring Costs topped out at $670000.0 in Q1 2020 and bottomed at -$699000.0 in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Chemomab Therapeutics | 959.23 Mn | 948.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | -699,000.00 |
| Sep 30, 2020 | 79,000.00 |
| Mar 31, 2020 | 670,000.00 |